{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T20:10:51Z","timestamp":1786997451194,"version":"build-2736575974"},"reference-count":13,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,8,1]],"date-time":"2021-08-01T00:00:00Z","timestamp":1627776000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","thrombosisresearch.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Thrombosis Research"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1016\/j.thromres.2021.06.002","type":"journal-article","created":{"date-parts":[[2021,6,7]],"date-time":"2021-06-07T01:48:14Z","timestamp":1623030494000},"page":"76-80","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Maximum intravenous alteplase dose for obese stroke patients is not associated with greater likelihood of worse outcomes"],"prefix":"10.1016","volume":"204","author":[{"given":"Kaushik","family":"Ravipati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roboan","family":"Guillen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Starlie","family":"Belnap","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anshul","family":"Saxena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emir","family":"Veledar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amy K.","family":"Starosciak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Felipe","family":"De Los Rios La Rosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.thromres.2021.06.002_bb0005","doi-asserted-by":"crossref","unstructured":"Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-PA Stroke Study Group, N. Engl. J. Med. 333(24) (1995) 1581\u20137. doi: https:\/\/doi.org\/10.1056\/NEJM199512143332401.","DOI":"10.1056\/NEJM199512143332401"},{"issue":"6","key":"10.1016\/j.thromres.2021.06.002_bb0010","doi-asserted-by":"crossref","first-page":"1615","DOI":"10.1161\/STROKEAHA.110.603514","article-title":"Is the maximum dose of 90 mg alteplase sufficient for patients with ischemic stroke weighing >100 kg?","volume":"42","author":"Diedler","year":"2011","journal-title":"Stroke"},{"key":"10.1016\/j.thromres.2021.06.002_bb0015","doi-asserted-by":"crossref","unstructured":"T.G. Brott, E.C. Haley, Jr., D.E. Levy, W. Barsan, J. Broderick, G.L. Sheppard, J. Spilker, G.L. Kongable, S. Massey, R. Reed, et al., Urgent therapy for stroke. Part I. Pilot study of tissue plasminogen activator administered within 90 minutes, Stroke 23(5) (1992) 632\u201340. doi: https:\/\/doi.org\/10.1161\/01.str.23.5.632.","DOI":"10.1161\/01.STR.23.5.632"},{"key":"10.1016\/j.thromres.2021.06.002_bb0020","doi-asserted-by":"crossref","unstructured":"E.C. Haley, Jr., D.E. Levy, T.G. Brott, G.L. Sheppard, M.C. Wong, G.L. Kongable, J.C. Torner, J.R. Marler, Urgent therapy for stroke. Part II. Pilot study of tissue plasminogen activator administered 91\u2013180 minutes from onset, Stroke 23(5) (1992) 641\u20135. doi: https:\/\/doi.org\/10.1161\/01.str.23.5.641.","DOI":"10.1161\/01.STR.23.5.641"},{"key":"10.1016\/j.thromres.2021.06.002_bb0025","doi-asserted-by":"crossref","unstructured":"C.S. Anderson, T. Robinson, R.I. Lindley, H. Arima, P.M. Lavados, T.H. Lee, J.P. Broderick, X. Chen, G. Chen, V.K. Sharma, J.S. Kim, N.H. Thang, Y. Cao, M.W. Parsons, C. Levi, Y. Huang, V.V. Olavarria, A.M. Demchuk, P.M. Bath, G.A. Donnan, S. Martins, O.M. Pontes-Neto, F. Silva, S. Ricci, C. Roffe, J. Pandian, L. Billot, M. Woodward, Q. Li, X. Wang, J. Wang, J. Chalmers, E. Investigators, Coordinators, Low-dose versus standard-dose intravenous alteplase in acute ischemic stroke, N. Engl. J. Med. 374(24) (2016) 2313\u201323. doi: https:\/\/doi.org\/10.1056\/NEJMoa1515510.","DOI":"10.1056\/NEJMoa1515510"},{"issue":"8","key":"10.1016\/j.thromres.2021.06.002_bb0030","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1001\/jama.2014.732","article-title":"Prevalence of childhood and adult obesity in the United States, 2011-2012","volume":"311","author":"Ogden","year":"2014","journal-title":"JAMA"},{"key":"10.1016\/j.thromres.2021.06.002_bb0035","unstructured":"C.M. Hales, M.D. Carroll, C.D. Fryar, C.L. Ogden, Prevalence of obesity and severe obesity among adults: United States 2017\u20132018, NCHS Data Brief 360 (2020) 1\u20138."},{"key":"10.1016\/j.thromres.2021.06.002_bb0040","unstructured":"Behaviors That Increase Risk for Stroke, 2020. https:\/\/www.cdc.gov\/stroke\/behavior.htm. (Accessed March 17, 2020)."},{"issue":"4","key":"10.1016\/j.thromres.2021.06.002_bb0045","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1016\/j.jstrokecerebrovasdis.2013.01.022","article-title":"Is there a decreased risk of intracerebral hemorrhage and mortality in obese patients treated with intravenous thrombolysis in acute ischemic stroke?","volume":"22","author":"Hassan","year":"2013","journal-title":"J. Stroke Cerebrovasc. Dis."},{"issue":"10","key":"10.1016\/j.thromres.2021.06.002_bb0050","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0164413","article-title":"No impact of body mass index on outcome in stroke patients treated with IV thrombolysis BMI and IV thrombolysis outcome","volume":"11","author":"Branscheidt","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.thromres.2021.06.002_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jns.2017.10.012","article-title":"The effect of metabolic syndrome and obesity on outcomes of acute ischemic stroke patients treated with systemic thrombolysis","volume":"383","author":"Bas","year":"2017","journal-title":"J. Neurol. Sci."},{"issue":"5","key":"10.1016\/j.thromres.2021.06.002_bb0060","doi-asserted-by":"crossref","first-page":"1041","DOI":"10.1016\/j.jstrokecerebrovasdis.2016.12.015","article-title":"Impact of tissue plasminogen activator dosing on patients weighing more than 100 kg on 3-month outcomes in acute ischemic stroke","volume":"26","author":"Garavaglia","year":"2017","journal-title":"J. Stroke Cerebrovasc. Dis."},{"key":"10.1016\/j.thromres.2021.06.002_bb0065","unstructured":"QuickFacts: Miami City, Florida; Miami-Dade County, Florida. https:\/\/www.census.gov\/quickfacts\/fact\/table\/miamicityflorida,miamidadecountyflorida\/PST045218. (Accessed March 17, 2020)."}],"container-title":["Thrombosis Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821003613?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049384821003613?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T17:45:48Z","timestamp":1758735948000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049384821003613"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,8]]},"references-count":13,"alternative-id":["S0049384821003613"],"URL":"https:\/\/doi.org\/10.1016\/j.thromres.2021.06.002","relation":{},"ISSN":["0049-3848"],"issn-type":[{"value":"0049-3848","type":"print"}],"subject":[],"published":{"date-parts":[[2021,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maximum intravenous alteplase dose for obese stroke patients is not associated with greater likelihood of worse outcomes","name":"articletitle","label":"Article Title"},{"value":"Thrombosis Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.thromres.2021.06.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}